{
    "xml": "<topic id=\"PHP1967\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/omalizumab\" basename=\"omalizumab\" title=\"OMALIZUMAB\">\n<title>OMALIZUMAB</title>\n<body>\n<data name=\"vtmid\">406442003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_805434570\" title=\"Monoclonal antibodies\">Monoclonal antibodies</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP71982\" outputclass=\"indicationsAndDose\" rev=\"1.34\" parent=\"/drugs/omalizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of severe persistent allergic asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Dose according to immunoglobulin E concentration and body-weight (consult product literature).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H<sub>1</sub> antihistamine treatment</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg every 4&#8239;weeks.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72025\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/omalizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Autoimmune disease</ph>; <ph outputclass=\"caution\">susceptibility to helminth infection&#8212;discontinue if infection does not respond to anthelmintic</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71945\" outputclass=\"sideEffects\" rev=\"1.23\" parent=\"/drugs/omalizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">sinusitis</ph>; <ph outputclass=\"sideEffect\">upper respiratory tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bronchospasm</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">influenza-like illness</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">pharyngitis</ph>; <ph outputclass=\"sideEffect\">photosensitivity</ph>; <ph outputclass=\"sideEffect\">postural hypotension</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angioedema</ph>; <ph outputclass=\"sideEffect\">antibody formation</ph>; <ph outputclass=\"sideEffect\">laryngoedema</ph>; <ph outputclass=\"sideEffect\">parasitic infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">arterial thromboembolic events</ph>; <ph outputclass=\"sideEffect\">Churg-Strauss syndrome</ph>; <ph outputclass=\"sideEffect\">joint swelling</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">serum sickness (including fever and lymphadenopathy)</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Churg-Strauss syndrome</p>\n<p>Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71970\" outputclass=\"pregnancy\" parent=\"/drugs/omalizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential&#8212;crosses the placenta.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72031\" outputclass=\"breastFeeding\" parent=\"/drugs/omalizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71994\" outputclass=\"hepaticImpairment\" parent=\"/drugs/omalizumab\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71960\" outputclass=\"renalImpairment\" parent=\"/drugs/omalizumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71904\" outputclass=\"nationalFunding\" rev=\"1.34\" parent=\"/drugs/omalizumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE </p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Omalizumab for previously treated chronic spontaneous urticaria (June 2015)</p>\r\n<p>Omalizumab is an option as add-on therapy for the treatment of severe chronic spontaneous urticaria in patients 12 years and over, only if:</p>\r\n<ul>\r\n<li>the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more,</li>\r\n<li>the patient's condition has not responded to standard treatment with H<sub>1</sub>-antihistamines and leukotriene receptor antagonists,</li>\r\n<li>omalizumab is stopped at or before the fourth dose if the condition has not responded,</li>\r\n<li>omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded and is restarted only if the condition relapses,</li>\r\n<li>omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy,</li>\r\n<li>the manufacturer provides omalizumab with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Patients currently receiving omalizumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"https://www.nice.org.uk/TA339\">www.nice.org.uk/TA339</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA278</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Omalizumab for severe persistent allergic asthma (April 2013)</p>\r\n<p>Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in patients aged 6 years and over:</p>\r\n<ul>\r\n<li>who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), <b>and</b>\r\n</li>\r\n<li>only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta<sub>2</sub> agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.</p>\r\n<p>Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA278\">www.nice.org.uk/TA278</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (December 2014) that omalizumab (<i>Xolair</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of chronic spontaneous urticaria in patients aged 12 years and over, who have had an inadequate response to combination therapy with H<sub>1</sub>-antihistamines, leukotriene receptor antagonists and H<sub>2</sub>-antihistamines, used according to current treatment guidelines.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1967-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/omalizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75747\" title=\"Solution for injection\" namespace=\"/drugs/omalizumab/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78111\" namespace=\"/treatment-summaries/antihistamines-allergen-immunotherapy-and-allergic-emergencies\" title=\"Antihistamines, allergen immunotherapy and allergic emergencies\" count=\"2\" rel=\"backlink\">Antihistamines, allergen immunotherapy and allergic emergencies</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78360\" namespace=\"/treatment-summaries/asthma\" title=\"Asthma\" count=\"1\" rel=\"backlink\">Asthma</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75747\" namespace=\"/drugs/omalizumab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1967",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/omalizumab",
    "basename": "omalizumab",
    "title": "OMALIZUMAB",
    "vtmid": "406442003",
    "drugClassification": [
        "Monoclonal antibodies"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of severe persistent allergic asthma",
                        "html": "Prophylaxis of severe persistent allergic asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Dose according to immunoglobulin E concentration and body-weight (consult product literature).",
                        "html": "<p>Dose according to immunoglobulin E concentration and body-weight (consult product literature).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H1 antihistamine treatment",
                        "html": "Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H<sub>1</sub> antihistamine treatment"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "300 mg every 4 weeks.",
                        "html": "<p>300&#8239;mg every 4&#8239;weeks.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Autoimmune disease",
                "html": "Autoimmune disease"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to helminth infection&#8212;discontinue if infection does not respond to anthelmintic",
                "html": "susceptibility to helminth infection&#8212;discontinue if infection does not respond to anthelmintic"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sinusitis",
                        "html": "sinusitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "upper respiratory tract infection",
                        "html": "upper respiratory tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Bronchospasm",
                        "html": "Bronchospasm",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "influenza-like illness",
                        "html": "influenza-like illness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pharyngitis",
                        "html": "pharyngitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "photosensitivity",
                        "html": "photosensitivity",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "postural hypotension",
                        "html": "postural hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Angioedema",
                        "html": "Angioedema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "antibody formation",
                        "html": "antibody formation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "laryngoedema",
                        "html": "laryngoedema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "parasitic infection",
                        "html": "parasitic infection",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arterial thromboembolic events",
                        "html": "arterial thromboembolic events",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Churg-Strauss syndrome",
                        "html": "Churg-Strauss syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "joint swelling",
                        "html": "joint swelling",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "serum sickness (including fever and lymphadenopathy)",
                        "html": "serum sickness (including fever and lymphadenopathy)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Churg-Strauss syndrome",
                "textContent": "Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy.",
                "html": "<p>Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy.</p>"
            },
            {
                "type": "advice",
                "title": "Hypersensitivity reactions",
                "textContent": "Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.",
                "html": "<p>Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential&#8212;crosses the placenta.",
                "html": "<p>Manufacturer advises avoid unless essential&#8212;crosses the placenta.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "https://www.nice.org.uk/TA339",
                        "label": "www.nice.org.uk/TA339"
                    }
                ],
                "fundingIdentifier": "NICE",
                "textContent": "Omalizumab for previously treated chronic spontaneous urticaria (June 2015) Omalizumab is an option as add-on therapy for the treatment of severe chronic spontaneous urticaria in patients 12 years and over, only if: the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more, the patient's condition has not responded to standard treatment with H1-antihistamines and leukotriene receptor antagonists, omalizumab is stopped at or before the fourth dose if the condition has not responded, omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded and is restarted only if the condition relapses, omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy, the manufacturer provides omalizumab with the discount agreed in the patient access scheme. Patients currently receiving omalizumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA339",
                "html": "<p outputclass=\"title\">Omalizumab for previously treated chronic spontaneous urticaria (June 2015)</p> <p>Omalizumab is an option as add-on therapy for the treatment of severe chronic spontaneous urticaria in patients 12 years and over, only if:</p> <ul> <li>the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more,</li> <li>the patient's condition has not responded to standard treatment with H<sub>1</sub>-antihistamines and leukotriene receptor antagonists,</li> <li>omalizumab is stopped at or before the fourth dose if the condition has not responded,</li> <li>omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded and is restarted only if the condition relapses,</li> <li>omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy,</li> <li>the manufacturer provides omalizumab with the discount agreed in the patient access scheme.</li> </ul> <p>Patients currently receiving omalizumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"https://www.nice.org.uk/TA339\">www.nice.org.uk/TA339</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA278",
                        "label": "www.nice.org.uk/TA278"
                    }
                ],
                "fundingIdentifier": "NICE TA278",
                "textContent": "Omalizumab for severe persistent allergic asthma (April 2013) Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in patients aged 6 years and over: who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), and only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme. Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta2 agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate. Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA278",
                "html": "<p outputclass=\"title\">Omalizumab for severe persistent allergic asthma (April 2013)</p> <p>Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in patients aged 6 years and over:</p> <ul> <li>who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), <b>and</b> </li> <li>only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.</li> </ul> <p>Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta<sub>2</sub> agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.</p> <p>Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA278\">www.nice.org.uk/TA278</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75747",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78111",
                "label": "Antihistamines, allergen immunotherapy and allergic emergencies",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78360",
                "label": "Asthma",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75747",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}